Atossa Therapeutics, Inc. focuses on the discovery and development of medicines in the areas of oncology and infectious diseases.The company's lead program is Endoxifen, an active metabolite of tamoxefen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized patients.
